In vitro effects of boron-containing compounds upon glioblastoma cells.
Boron-neutron capture therapy (BNCT) is currently under investigation as a novel therapeutic modality for glioblastoma. This study was undertaken to determine whether boron-containing compounds 4-borono-2-fluoro-D,L-phenylalanine (FBPA) and FBPA-fructose have direct effects upon kinetics of A172, a glioblastoma cell line. Flow cytometry analyzed cell-cycle distribution and S-phase kinetics (bromo deoxyuridine [BUdR] incorporation). BUdR incorporation was increased during a 1-hr pulse after 24-hr or 72-hr exposure of cells to varying concentrations of FBPA or FBPA-fructose. Results suggest that boron-containing compounds may effect cell kinetics apart from neutron activation, and this effect should be further evaluated for potential impact upon tumor responsiveness to BNCT.
Bailey
S F
SF
Department of Pathology, University of Tennessee Medical Center, Knoxville 37920-6999, USA.
Kabalka
G W
GW
Fuhr
J E
JE
D001896:Boron Compounds / Q000494:pharmacology*; D016754:Boron Neutron Capture Therapy; D001973:Bromodeoxyuridine / Q000378:metabolism; D002453:Cell Cycle / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D004261:DNA Replication / Q000187:drug effects; D005434:Flow Cytometry; D005462:Fluorine Radioisotopes / Q000494:pharmacology*; D005632:Fructose / Q000494:pharmacology; D005909:Glioblastoma / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D006801:Humans; D010649:Phenylalanine / Q000031:analogs & derivatives* / Q000494:pharmacology; D014407:Tumor Cells, Cultured
D001896:Boron Compounds; D005462:Fluorine Radioisotopes; C072915:4-borono-2-fluorophenylalanine; D005632:Fructose; D010649:Phenylalanine; D001973:Bromodeoxyuridine